TY - JOUR
T1 - Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
T2 - Predictors of Clinical and Radiographic Failure from 636 Embolizations
AU - Salem, Mohamed M.
AU - Kuybu, Okkes
AU - Hoang, Alex Nguyen
AU - Baig, Ammad A.
AU - Khorasanizadeh, Mirhojjat
AU - Baker, Cordell
AU - Hunsaker, Joshua C.
AU - Mendez, Aldo A.
AU - Cortez, Gustavo
AU - Davies, Jason M.
AU - Narayanan, Sandra
AU - Cawley, C. Michael
AU - Riina, Howard A.
AU - Moore, Justin M.
AU - Spiotta, Alejandro M.
AU - Khalessi, Alexander A.
AU - Howard, Brian M.
AU - Hanel, Ricardo
AU - Tanweer, Omar
AU - Levy, Elad I.
AU - Grandhi, Ramesh
AU - Lang, Michael J.
AU - Siddiqui, Adnan H.
AU - Kan, Peter
AU - Ogilvy, Christopher S.
AU - Gross, Bradley A.
AU - Thomas, Ajith J.
AU - Jankowitz, Brian T.
AU - Burkhardt, Jan Karl
N1 - Publisher Copyright:
© RSNA, 2023.
PY - 2023/5
Y1 - 2023/5
N2 - Background: Knowledge regarding predictors of clinical and radiographic failures of middle meningeal artery (MMA) embolization (MMAE) treatment for chronic subdural hematoma (CSDH) is limited. Purpose: To identify predictors of MMAE treatment failure for CSDH. Materials and Methods: In this retrospective study, consecutive patients who underwent MMAE for CSDH from February 2018 to April 2022 at 13 U.S. centers were included. Clinical failure was defined as hematoma reaccumulation and/or neurologic deterioration requiring rescue surgery. Radiographic failure was defined as a maximal hematoma thickness reduction less than 50% at last imaging (minimum 2 weeks of head CT follow-up). Multivariable logistic regression models were constructed to identify independent failure predictors, controlling for age, sex, concurrent surgical evacuation, midline shift, hematoma thickness, and pretreatment baseline antiplatelet and anticoagulation therapy. Results: Overall, 530 patients (mean age, 71.9 years ± 12.8 [SD]; 386 men; 106 with bilateral lesions) underwent 636 MMAE procedures. At presentation, the median CSDH thickness was 15 mm and 31.3% (166 of 530) and 21.7% (115 of 530) of patients were receiving antiplatelet and anticoagulation medications, respectively. Clinical failure occurred in 36 of 530 patients (6.8%, over a median follow-up of 4.1 months) and radiographic failure occurred in 26.3% (137 of 522) of procedures. At multivariable analysis, independent predictors of clinical failure were pretreatment anticoagulation therapy (odds ratio [OR], 3.23; P =.007) and an MMA diameter less than 1.5 mm (OR, 2.52; P =.027), while liquid embolic agents were associated with nonfailure (OR, 0.32; P =.011). For radiographic failure, female sex (OR, 0.36; P =.001), concurrent surgical evacuation (OR, 0.43; P =.009), and a longer imaging follow-up time were associated with nonfailure. Conversely, MMA diameter less than 1.5 mm (OR, 1.7; P =.044), midline shift (OR, 1.1; P =.02), and superselective MMA catheterization (without targeting the main MMA trunk) (OR, 2; P =.029) were associated with radiographic failure. Sensitivity analyses retained these associations. Conclusion: Multiple independent predictors of failure of MMAE treatment for chronic subdural hematomas were identified, with small diameter (<1.5 mm) being the only factor independently associated with both clinical and radiographic failures.
AB - Background: Knowledge regarding predictors of clinical and radiographic failures of middle meningeal artery (MMA) embolization (MMAE) treatment for chronic subdural hematoma (CSDH) is limited. Purpose: To identify predictors of MMAE treatment failure for CSDH. Materials and Methods: In this retrospective study, consecutive patients who underwent MMAE for CSDH from February 2018 to April 2022 at 13 U.S. centers were included. Clinical failure was defined as hematoma reaccumulation and/or neurologic deterioration requiring rescue surgery. Radiographic failure was defined as a maximal hematoma thickness reduction less than 50% at last imaging (minimum 2 weeks of head CT follow-up). Multivariable logistic regression models were constructed to identify independent failure predictors, controlling for age, sex, concurrent surgical evacuation, midline shift, hematoma thickness, and pretreatment baseline antiplatelet and anticoagulation therapy. Results: Overall, 530 patients (mean age, 71.9 years ± 12.8 [SD]; 386 men; 106 with bilateral lesions) underwent 636 MMAE procedures. At presentation, the median CSDH thickness was 15 mm and 31.3% (166 of 530) and 21.7% (115 of 530) of patients were receiving antiplatelet and anticoagulation medications, respectively. Clinical failure occurred in 36 of 530 patients (6.8%, over a median follow-up of 4.1 months) and radiographic failure occurred in 26.3% (137 of 522) of procedures. At multivariable analysis, independent predictors of clinical failure were pretreatment anticoagulation therapy (odds ratio [OR], 3.23; P =.007) and an MMA diameter less than 1.5 mm (OR, 2.52; P =.027), while liquid embolic agents were associated with nonfailure (OR, 0.32; P =.011). For radiographic failure, female sex (OR, 0.36; P =.001), concurrent surgical evacuation (OR, 0.43; P =.009), and a longer imaging follow-up time were associated with nonfailure. Conversely, MMA diameter less than 1.5 mm (OR, 1.7; P =.044), midline shift (OR, 1.1; P =.02), and superselective MMA catheterization (without targeting the main MMA trunk) (OR, 2; P =.029) were associated with radiographic failure. Sensitivity analyses retained these associations. Conclusion: Multiple independent predictors of failure of MMAE treatment for chronic subdural hematomas were identified, with small diameter (<1.5 mm) being the only factor independently associated with both clinical and radiographic failures.
UR - https://www.scopus.com/pages/publications/85159781377
UR - https://www.scopus.com/pages/publications/85159781377#tab=citedBy
U2 - 10.1148/radiol.222045
DO - 10.1148/radiol.222045
M3 - Article
C2 - 37070990
AN - SCOPUS:85159781377
SN - 0033-8419
VL - 307
SP - e222045
JO - Radiology
JF - Radiology
IS - 4
M1 - e222045
ER -